Year: 2014
Type: article
Abstract: OBJECTIVE: To investigate the effect of hepatitis C virus (HCV) on neurocognitive performance in chronically HIV-infected patients enrolled in the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) study. METHODS: A total of 1,582 participants in CHARTER who were tested for HCV antibody underwent neurocognitive testing; serum HCV RNA was available for 346 seropositive patients. Neurocognitive performance was compared in 408 HCV-seropositive and 1,174 HCV-seronegative participants and in a subset of 160 seropositive and 707 seronegative participants without serious comorbid neurologic conditions that might impair neurocognitive performance, using linear regression and taking into account HIV-associated and demographic factors (including IV drug use) and liver function. RESULTS: Neurocognitive performance characterized by global deficit scores and the proportion of individuals who were impaired were the same in the HCV-seropositive and HCV-seronegative groups. In univariable analyses in the entire sample, only verbal domain scores showed small statistically different superior performance in the HCV+ group that was not evident in multivariable analysis. In the subgroup without significant comorbidities, scores in all 7 domains of neurocognitive functioning did not differ by HCV serostatus. Among the HCV-seropositive participants, there was no association between neurocognitive performance and serum HCV RNA concentration. CONCLUSION: In HIV-infected patients, HCV coinfection does not contribute to neurocognitive impairment, at least in the absence of substantial HCV-associated liver damage, which was not evident in our cohort.
Source: Neurology
Authors: David B. Clifford, Florin Vaida, Yu-Ting Kao, Donald R. Franklin, Scott L. Letendre, Ann C. Collier, Christina M. Marra, Benjamin B. Gelman, Justin C. McArthur, Susan Morgello, David M. Simpson, Igor Grant, Robert K. Heaton, For the CHARTER Group, Igor Grant, Scott L. Letendre, Ronald J. Ellis, Thomas D. Marcotte, Donald Franklin, Ronald J. Ellis, J. Allen McCutchan, Scott Letendre, Davey M. Smith, Robert K. Heaton, J. Hampton Atkinson, Matthew Dawson, Christine Fennema-Notestine, Michael J Taylor, Rebecca Theilmann, Anthony C. Gamst, Clint Cushman, Ian Abramson, Florin Vaida, Reena Deutsch, Justin McArthur, Vincent Rogalski, Susan Morgello, David Simpson, Letty Mintz, J. Allen McCutchan, Kaori Phillips, Ann Collier, Christina Marra, Trudy Jones, Benjamin Gelman, David Clifford, Muhammad Al-Lozi, Mengesha Teshome
Language: English
Topic: HIV Research and Treatment
Subfield: Virology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: bronze
Awards: G1025459590, G1047363770, G1286378763, California NeuroAIDS Tissue Network (CNTN), G1551097431, WASHINGTON UNIVERSITY AIDS CLINICAL TRIALS UNIT, G1727540074, G1841559972, G1982323743, HIV Neurocognitive Disorders: A Randomized Clinical Trial of CNS-Targeted HAART, Translational Methamphetamine AIDS Research Center (TMARC), G2133922972, G2135258891, Clinical Trial of CNS Penetrating ART to Prevent NeuroAIDS in China, G2349863769, G2421492189, G25173860, Washington University Network of Excellence in Neuroscience Clinical Trials Site, G2618565798, G2638554112, G3003581592, CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER), G3350118538, G3471390838, G4180866436, NEUROAIDS: EFFECTS OF METHAMPHETAMINE AND HCV, G5209633835, Texas NeuroAIDS Research Center, G6109780786, G6391991693, G6464879405, Proteomic Strategies for AIDS and Drug Abuse - HIV and METH CNS Synergy, Functional Neuroimaging of Cognitive Dysfunction in HIV-HCV Co-Infection, Low cost multi-pathogen laser diagnostics for HIV and AIDS Co-infections, G9000065455, G9000133689, HIV Neurobehavioral Research Center, JHU Center for the Advancement of HIV Neurotherapeutics (JHU CAHN), G902710719, G936311976
OpenAlex ID: W2134352080